Billionaire Steve Cohen’s Cheap Stock Picks Include Discover

Avago Technologies Ltd (NASDAQ:AVGO), an $8.4 billion market cap designer of semiconductor products, was another of Cohen’s stock picks with fairly low earnings multiples; the stock trades at trailing and forward P/Es of 15 and 12, respectively. Avago’s stock has sold off just a bit in the last year against a rising market, and revenue growth last quarter was fairly low versus a year earlier (though of course little growth is required at this pricing). Lee Ainslie’s Maverick Capital, even after cutting its stake, was the largest shareholder in our database of 13F filings.

Cohen and his team were buying oil major Occidental Petroleum Corporation (NYSE:OXY), closing December with 1.8 million shares in their portfolio. Occidental made our list of the most popular energy stocks among hedge funds for the fourth quarter of 2012 (check out more energy stocks hedge funds love). The stock trades at 15 times trailing earnings, which is actually higher than many of its peers, though net income is expected to improve to the point where the forward P/E is 11. That is certainly low in absolute terms though we would certainly explore Exxon Mobil Corporation (NYSE:XOM) and other oil majors as alternatives.

SAC had owned a small position in Discover Financial Services (NYSE:DFS) at the beginning of October but built it up to 3.4 million shares by the end of 2012. Discover is valued at 9 times trailing earnings, whether we look at trailing results or consensus for the fiscal year ending in November 2014. The financials actually look good as well with decent growth rates in net income entirely due to increasing revenue. Cliff Ansess’s AQR Capital Management roughly doubled the size of its own position in Discover (see more stocks AQR was buying).

Disclosure: I own no shares of any stocks mentioned in this article.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!